Bolton hospital issues warning as infectious disease on the rise in GM
Health officials are urging people to check their vaccination status, with particular concern for children, pregnant women and those with weakened immune systems, who are more at risk of serious complications from the disease.
Measles is highly infectious and spreads easily among unvaccinated people, especially in settings such as nurseries and schools.
Just a cough or sneeze is enough to pass the virus on.
The infection can cause serious illness, including pneumonia and meningitis, and around one in five people with measles will require hospital treatment. In very rare cases, the disease can be fatal.
READ MORE:
Bolton NHS waiting lists fall by more than 7000 people
Bolton pensioners call to save independent Healthwatch
GP Patient Survey 2025: Best and worst in Bolton
Symptoms typically appear seven to 10 days after exposure and can include a high fever, cold-like symptoms, sore eyes and a red-brown rash. Small white spots may also appear inside the cheeks and lips for a few days.
The best protection against measles is the MMR (measles, mumps and rubella) vaccine. Two doses are needed for full protection, and the jab is available free of charge from GP surgeries.
Cases of measles are on the rise in Greater Manchester. (Image: Bolton NHS FT)
It's never too late to catch up on missed vaccinations, and adults as well as children are encouraged to check their records or speak to their GP.
Parents can refer to their child's Red Book, check the NHS app, or contact their practice directly.
A non-porcine version of the vaccine (Priorix) is available for those who avoid pork products, and people who are immunocompromised are advised to consult a GP or specialist before receiving the jab.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Medscape
44 minutes ago
- Medscape
Can Weight Loss Boost Pregnancy Rates?
A 10%-25% weight loss can help women considered overweight or having obesity become pregnant — even if they weren't trying to conceive — and reduce their chances for some pregnancy-related conditions and complications, according to a new study on reproduction. The study included patient data from nearly 250,000 women in the UK aged 18-40 years who had a BMI ≥ 25, which is considered overweight. BMI measures an estimate of body fat based on height and weight. Patients with obesity, who have a BMI ≥ 30, were also part of the study. Women in these categories who dropped the weight with a median loss of 14% had a small increase, about 5%, of becoming pregnant in the following 3 years compared with those with stable weight, according to the study published in Human Reproduction by Oxford University Press on behalf of the European Society of Human Reproduction and Embryology. The study used patient data collected from primary care practices linked to hospital records in England between January 2000 and May 2022. Nearly 80% of the women in the study kept a stable weight and the rest lost weight. Of the women who became pregnant (9%), those who lost weight had a 'statistically significant reduction' in the risk for gestational diabetes and emergency caesarean section, the study found. The women who lost weight also saw reduced pregnancy-induced hypertension with fewer babies born considered large for their gestational age compared with women of stable weight. Novo Nordisk — the maker of weight-loss drug Wegovy and diabetes drug Ozempic — funded the study, and most of the study authors work for the pharmaceutical company and/or hold shares or stock. Medscape Medical News asked a few clinicians, including Ob/Gyns with specialized training to treat patients with obesity, to weigh in on the study's findings. 'There is a lot of data to support that women that have obesity or are overweight have higher risks in their pregnancy but also have a more difficult time conceiving,' said Deidre Neyhart-McIntosh, MD, an Ob/Gyn with the Cleveland Clinic, Cleveland, who is trained in obesity medicine. The study shows that the healthier a woman can be prior to conceiving, the easier it will likely be for her to conceive and have a more successful pregnancy, McIntosh said. In her practice, McIntosh has seen that women who lose even 5% of their body weight can reduce their blood pressure, glucose, lipids, inflammation, and cardiovascular risk. McIntosh said she speaks with patients who want to be pregnant about the risks of having obesity, such as diabetes, hypertension, preeclampsia, pre-term delivery, or caesarian section of a large baby. She advises women to try to lose weight 6 months before they want to become pregnant and to study the habits that help them lose weight to continue eating healthy during pregnancy. Patients who are overweight may seek her help if they have difficulty becoming pregnant or have risk factors such as high blood pressure or prediabetes, she said. In those cases, McIntosh might discuss nutrition, exercise, or prescribe weight-loss medicine to help them improve their chances of a healthy pregnancy. McIntosh finds that most of her patients have tried other methods to lose weight before requesting weight-loss medicine. Depending on the medication, they should stop the drugs either immediately prior to conceiving or 2 months beforehand. Despite the study's connection to a weight-loss drug maker, McIntosh said she still believes the findings are valid. 'Obviously, we're going to pick out some of the biases, but overall, they looked at a wide variety of women and didn't focus on women that were just taking weight-loss medications either,' she said. Weight-Loss Medications The FDA has approved some of the newer medications for chronic weight management in adults with obesity, or if they are overweight, with at least one weight-related condition such as high blood pressure, type 2 diabetes, or high cholesterol. Johanna Finkle, MD, an Ob/Gyn and weight-loss specialist with the University of Kansas Health System, Kansas City, Kansas, said that although the study doesn't specifically mention weight-loss drugs, a weight loss of 10%-25% is typically only seen in women taking the medicine for weight loss. From her experience, diet and exercise only produce a 3%-5% weight loss in a year, Finkle said. The study also cited previous research with different diets and exercise that didn't show decreased pregnancy complications or increased spontaneous conception, she noted. Finkle believes the new study looked at weight loss because women are losing significant weight on the medicines Novo Nordisk manufactures, namely GLP-1 receptor agonists. 'The question that they are trying to answer: Is this going to be beneficial to a preconception population and how much weight loss [is optimal] because these drugs are producing more weight loss than we see with diet and exercise alone,' she said. Optimal Weight Loss 'Right now, what we counsel is about 10% weight loss of body weight prior to pregnancy,' Finkle said. 'Any weight loss may be beneficial.' There are also risks to losing too much weight, especially in patients losing 30% of their body weight, she said. 'What I'm seeing in my patients is sometimes they're not consuming enough calories or even enough water,' Finkle said. 'I'm having to remind them that they need to eat more frequently. We discuss sufficient protein.' Others may experience hair loss. When patients lose a significant amount of weight, it can affect pregnancy. Patients who went through bariatric surgery have a risk for preterm delivery, Finkle said. 'I worry about small-for-gestational-age babies and an increased risk for miscarriage when people have a rapid trajectory of weight loss,' she said. Finkle said she counsels patients who are rapidly losing weight to try not to conceive while on the medication because 'the data on teratogenic risk of the weight-loss medications is not yet known.' Ideally, patients who want to lose weight before they conceive should come to her a year in advance, Finkle said. 'But if they're wanting to conceive in 3 months, then we discuss healthy behaviors, lifestyle, nutrition, and exercise counseling. We discuss: What is your goal? When do you want to conceive and how does weight loss play a role in that? How much weight loss can we achieve?' she said. Research Implications While previous research may have focused on the outcomes of women undergoing fertility treatment, the Novo Nordisk study wasn't restricted to women trying to conceive, so study authors said that the benefits of weight loss may be greater in women who are actively trying to become pregnant. Erin LeBlanc, MD, who conducts similar research about weight loss and pregnancy, believes the Novo Nordisk study provides further evidence that women having trouble becoming pregnant because they are overweight or have obesity could benefit from weight loss. In other words, if having a higher BMI is associated with decreased fertility rates, weight loss among that population could have the opposite impact, she said. LeBlanc, an epidemiologist and endocrinologist with the Kaiser Permanente Center for Health Research, said the Novo Nordisk study also aligns with research she led showing that women who lost weight had lower rates of gestational diabetes in early pregnancy. Because some women in the clinical trial gained weight back later in pregnancy, she stressed the importance of weight management throughout pregnancy. Women in her study who met with health coaches weekly for 6 months and then monthly for 18 months or until the end of their pregnancy were able to start pregnancy at a healthier weight. However, they experienced more weight gain during pregnancy, likely because it was challenging to maintain the healthy lifestyle changes they made prepregnancy without ongoing support, she said of the study originally published in 2021 in the American Journal of Obstetrics & Gynecology. ' What I would say from my research is that if women have been able to lose weight before pregnancy, they just need to be sure that they get support during pregnancy to help them to maintain a healthy lifestyle,' LeBlanc said. LeBlanc also said the new study may help inform future recommendations from the National Academy of Medicine, formerly the Institute of Medicine, which advised in 2009 that women achieve a healthy weight before becoming pregnant and remain within the gestational weight gain guidelines during pregnancy. Women with a healthy weight should gain 25-35 pounds; women who are overweight, 15-25 pounds; and women with obesity, 11-20 pounds, according to those guidelines. Study Limitations Among the limitations of the study, Finkle said using participants from the UK cannot necessarily be applied to those from the US. 'They did not cite the composition of their patient population,' she said. 'The United States is very diverse.' Finkle said that the median age of the patients (30 years) is also important to note. 'When you are talking about fertility, age plays a much larger role than necessarily body weight when looking at someone's ability to conceive.' Study authors said they didn't know whether women had intended to become pregnant or whether that intention was why they lost weight. Including women who don't intend to conceive may also affect the findings by underestimating the relationship between weight loss and chance of pregnancy, the authors said. And while they observed a link between weight loss and increased chance of pregnancy, they said they couldn't imply higher pregnancy rates were caused by weight loss. In her practice, Finkle often sees patients trying to lose weight prior to conception. 'So if more patients in the group that was actually trying to lose weight wanted to conceive, they're going to have higher rates of pregnancy than a weight stable group that maybe wasn't trying or had any intention of conceiving and were using maybe other methods to prevent pregnancy,' she said. Overall, Finkle found promising the study's finding of a small increase in conception from weight loss. She said more studies are needed to look at weight loss and pregnancy, including how weight gain during pregnancy affects the delivery and health of the mother and child. 'There's this phenomenon called weight cycling,' Finkle said. 'You may lose weight, then regain the same — or more — during pregnancy, and the question becomes: How will that affect outcomes such as large-for-gestational-age babies, cesarean-section deliveries, or hypertensive disorders? Many questions remain unanswered.'
Yahoo
an hour ago
- Yahoo
Diamonds could help detect cancer using groundbreaking new technique
Scientists have developed a diamond-based sensor that could make it easier for doctors to detect the spread of cancer. Researchers at the University of Warwick have created a handheld device that is designed to trace tiny magnetic particles injected into the body. The scientists said this offers a non-toxic alternative to radioactive tracers and dyes currently used in hospitals. Metastasis, when cancer cells spread from the original tumour to other parts of the body, is one of the most serious challenges in cancer treatment. Doctors often rely on tests to see whether the cancer has reached the lymph nodes – the areas of tissue that filter fluid in your body for harmful substances – which can guide decisions about surgery and further care. The findings, published in Physical Review Applied, describe how diamonds can be used to build a highly sensitive sensor capable of identifying the magnetic tracer fluid injected into a tumour. This fluid, made up of iron oxide nanoparticles, travels through the body alongside cancer cells, revealing whether they have reached the lymph nodes, the researchers said. Lead author Alex Newman, a PhD student in Warwick University's physics department, said the new tool could improve the way doctors find cancer in keyhole and endoscopic surgery. 'There is a real demand for versatile non-toxic means of finding cancer,' he said. 'For this new diamond-based sensor, we managed to get the size of the sensor head down to just 10 millimetres, which means it is the first diamond sensor to be able to detect magnetic tracer fluid while being small enough for endoscopic use and keyhole surgery.' Mr Newman added that the device was extremely sensitive, capable of detecting just one hundredth of the typical dose of magnetic tracer fluid. The design uses a diamond measuring only half a cubic millimetre alongside a small permanent magnet, the scientists said They added that this compact structure means there is no need for bulky electronics, allowing the sensor to be used by hand in operating rooms. Professor Gavin Morley, who leads the research group, said the breakthrough was possible thanks to nitrogen vacancy centres inside the diamond. 'These allow the diamond to detect very small changes in the magnetic field and give the diamonds a lovely pink colour,' he said. He added that the technology could also have uses beyond medicine, including in spacecraft and fusion power. Current techniques for tracing cancer cells rely on radioactive tracers, which not all hospitals can access, or blue dyes, which trigger allergic reactions in some patients, the researchers said. Clinicians involved in this new project believe the new diamond sensor could help avoid these complications. Stuart Robertson, a consultant breast cancer surgeon at University Hospitals Coventry and Warwickshire, said he was already using magnetic localisation in his work. He added that it offers more advantages over traditional techniques. Researchers say the device could eventually be applied to various cancers, including lung, liver, colorectal and oesophageal tumours.
Medscape
an hour ago
- Medscape
NICE Recommends Six Digital Platforms for Cardiac Rehab
The National Institute for Health and Care Excellence (NICE) has conditionally recommended six online platforms to support cardiac rehabilitation for adults with cardiovascular disease (CVD). The draft guidance allows the technologies to be used across the NHS for a 3-year trial period. Patients will be able to complete rehabilitation at home using smartphones, tablets, or computers. The platforms are Activate Your Heart, D REACH-HF, Digital Heart Manual, Gro Health HeartBuddy, KiActiv, and myHeart. They provide services such as exercise programmes, CVD education, dietary advice, medication management, and psychological support. Some also incorporate wearable devices to monitor activity levels. Addressing Low Participation Cardiac rehabilitation is a proven therapy that lowers the risk for repeat cardiac events and hospital readmissions. Yet, participation in traditional, in-person programmes remains low. In 2023, only 41% of eligible patients with acute coronary syndrome and 13% of those with heart failure in England took part. Digital platforms aim to improve access, particularly among groups with historically low participation rates. These include women, younger patients, ethnic minorities, and those unable to attend in-person sessions due to work, travel, or other commitments. Dr Anastasia Chalkidou, NICE's HealthTech programme director, said that the platforms 'offer real potential to transform how cardiac rehabilitation is offered to people to meet their individual circumstances,' adding that 'early data is promising and suggests, with safeguards in place, more people should now be given the opportunity to use these new technologies.' Evidence and Safeguards Clinical data are already available for several platforms. Activate Your Heart has been evaluated in three studies, including two randomised controlled trials (RCTs), while KiActiv has two studies, including one RCT, and myHeart has been assessed in two trials, including one RCT. Results suggest that digital rehabilitation can improve exercise capacity, cardiovascular risk profiles, and health-related quality of life. During the 3-year trial, evidence will be collected on clinical outcomes, uptake among diverse patient groups, cost-effectiveness, potential adverse events, and comparisons with standard rehabilitation. The conditional recommendation forms part of NICE's Early Value Assessment process. Following the trial, NICE will review the data and decide whether the technologies should be rolled out more widely across the NHS. NICE stressed that the recommended platforms should be used only after a full clinical assessment by a trained NHS professional to ensure they are suitable for each patient. Not all patients will be appropriate for digital rehabilitation, as barriers such as limited digital literacy and lack of access to devices may prevent some patients from taking part. Clinicians should also be aware that additional support may be needed for certain groups, including older adults, people with disabilities, those experiencing homelessness, and individuals for whom English is not a first language. Further Research Seven additional platforms — Beat Better, Datos Health, Get Ready, Luscii Vitals, Pumping Marvellous Cardiac Rehab Platform, R Plus Health, and Sword Move — require further research before routine NHS use. They should be offered only in research settings. A consultation on the draft recommendations is open until 3 September 2025, with comments invited via the NICE website.
